
Global NASH Drug Pipeline Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global NASH Drug Pipeline market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the NASH Drug Pipeline market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the NASH Drug Pipeline market include 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Allergan and ChemomAb Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for NASH Drug Pipeline, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of NASH Drug Pipeline, also provides the sales of main regions and countries. Of the upcoming market potential for NASH Drug Pipeline, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the NASH Drug Pipeline sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global NASH Drug Pipeline market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for NASH Drug Pipeline sales, projected growth trends, production technology, application and end-user industry.
NASH Drug Pipeline Segment by Company
89bio Inc
ABIONYX Pharma SA
Abivax SA
Abliva AB
Acquist Therapeutics
AdAlta Ltd
Afimmune Biopharma Ltd
Allergan
ChemomAb Ltd
Dicerna Pharmaceuticals Inc
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Inc
Engitix Ltd
Galectin
Genfit
Gilead
Heprotech Inc
Hinova Pharmaceuticals Inc
HK inno.N Corp
HotSpot Therapeutics Inc
Immuron
Intercept
Madrigal
Zhejiang Doer Biologics Corp
NASH Drug Pipeline Segment by Type
By Molecule Types
By Route of Administration:
By Mechanism of Action
NASH Drug Pipeline Segment by Application
Clinical
Academic Research
NASH Drug Pipeline Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global NASH Drug Pipeline status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions NASH Drug Pipeline market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify NASH Drug Pipeline significant trends, drivers, influence factors in global and regions.
6. To analyze NASH Drug Pipeline competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NASH Drug Pipeline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NASH Drug Pipeline and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NASH Drug Pipeline.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the NASH Drug Pipeline market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NASH Drug Pipeline industry.
Chapter 3: Detailed analysis of NASH Drug Pipeline manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of NASH Drug Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of NASH Drug Pipeline in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global NASH Drug Pipeline market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the NASH Drug Pipeline market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for NASH Drug Pipeline is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the NASH Drug Pipeline market include 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Allergan and ChemomAb Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for NASH Drug Pipeline, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of NASH Drug Pipeline, also provides the sales of main regions and countries. Of the upcoming market potential for NASH Drug Pipeline, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the NASH Drug Pipeline sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global NASH Drug Pipeline market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for NASH Drug Pipeline sales, projected growth trends, production technology, application and end-user industry.
NASH Drug Pipeline Segment by Company
89bio Inc
ABIONYX Pharma SA
Abivax SA
Abliva AB
Acquist Therapeutics
AdAlta Ltd
Afimmune Biopharma Ltd
Allergan
ChemomAb Ltd
Dicerna Pharmaceuticals Inc
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Inc
Engitix Ltd
Galectin
Genfit
Gilead
Heprotech Inc
Hinova Pharmaceuticals Inc
HK inno.N Corp
HotSpot Therapeutics Inc
Immuron
Intercept
Madrigal
Zhejiang Doer Biologics Corp
NASH Drug Pipeline Segment by Type
By Molecule Types
By Route of Administration:
By Mechanism of Action
NASH Drug Pipeline Segment by Application
Clinical
Academic Research
NASH Drug Pipeline Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global NASH Drug Pipeline status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions NASH Drug Pipeline market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify NASH Drug Pipeline significant trends, drivers, influence factors in global and regions.
6. To analyze NASH Drug Pipeline competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NASH Drug Pipeline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NASH Drug Pipeline and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NASH Drug Pipeline.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the NASH Drug Pipeline market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NASH Drug Pipeline industry.
Chapter 3: Detailed analysis of NASH Drug Pipeline manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of NASH Drug Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of NASH Drug Pipeline in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
215 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global NASH Drug Pipeline Sales Value (2020-2031)
- 1.2.2 Global NASH Drug Pipeline Sales Volume (2020-2031)
- 1.2.3 Global NASH Drug Pipeline Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 NASH Drug Pipeline Market Dynamics
- 2.1 NASH Drug Pipeline Industry Trends
- 2.2 NASH Drug Pipeline Industry Drivers
- 2.3 NASH Drug Pipeline Industry Opportunities and Challenges
- 2.4 NASH Drug Pipeline Industry Restraints
- 3 NASH Drug Pipeline Market by Company
- 3.1 Global NASH Drug Pipeline Company Revenue Ranking in 2024
- 3.2 Global NASH Drug Pipeline Revenue by Company (2020-2025)
- 3.3 Global NASH Drug Pipeline Sales Volume by Company (2020-2025)
- 3.4 Global NASH Drug Pipeline Average Price by Company (2020-2025)
- 3.5 Global NASH Drug Pipeline Company Ranking (2023-2025)
- 3.6 Global NASH Drug Pipeline Company Manufacturing Base and Headquarters
- 3.7 Global NASH Drug Pipeline Company Product Type and Application
- 3.8 Global NASH Drug Pipeline Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global NASH Drug Pipeline Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 NASH Drug Pipeline Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 NASH Drug Pipeline Market by Type
- 4.1 NASH Drug Pipeline Type Introduction
- 4.1.1 By Molecule Types
- 4.1.2 By Route of Administration:
- 4.1.3 By Mechanism of Action
- 4.2 Global NASH Drug Pipeline Sales Volume by Type
- 4.2.1 Global NASH Drug Pipeline Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global NASH Drug Pipeline Sales Volume by Type (2020-2031)
- 4.2.3 Global NASH Drug Pipeline Sales Volume Share by Type (2020-2031)
- 4.3 Global NASH Drug Pipeline Sales Value by Type
- 4.3.1 Global NASH Drug Pipeline Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global NASH Drug Pipeline Sales Value by Type (2020-2031)
- 4.3.3 Global NASH Drug Pipeline Sales Value Share by Type (2020-2031)
- 5 NASH Drug Pipeline Market by Application
- 5.1 NASH Drug Pipeline Application Introduction
- 5.1.1 Clinical
- 5.1.2 Academic Research
- 5.2 Global NASH Drug Pipeline Sales Volume by Application
- 5.2.1 Global NASH Drug Pipeline Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global NASH Drug Pipeline Sales Volume by Application (2020-2031)
- 5.2.3 Global NASH Drug Pipeline Sales Volume Share by Application (2020-2031)
- 5.3 Global NASH Drug Pipeline Sales Value by Application
- 5.3.1 Global NASH Drug Pipeline Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global NASH Drug Pipeline Sales Value by Application (2020-2031)
- 5.3.3 Global NASH Drug Pipeline Sales Value Share by Application (2020-2031)
- 6 NASH Drug Pipeline Regional Sales and Value Analysis
- 6.1 Global NASH Drug Pipeline Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global NASH Drug Pipeline Sales by Region (2020-2031)
- 6.2.1 Global NASH Drug Pipeline Sales by Region: 2020-2025
- 6.2.2 Global NASH Drug Pipeline Sales by Region (2026-2031)
- 6.3 Global NASH Drug Pipeline Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global NASH Drug Pipeline Sales Value by Region (2020-2031)
- 6.4.1 Global NASH Drug Pipeline Sales Value by Region: 2020-2025
- 6.4.2 Global NASH Drug Pipeline Sales Value by Region (2026-2031)
- 6.5 Global NASH Drug Pipeline Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America NASH Drug Pipeline Sales Value (2020-2031)
- 6.6.2 North America NASH Drug Pipeline Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe NASH Drug Pipeline Sales Value (2020-2031)
- 6.7.2 Europe NASH Drug Pipeline Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific NASH Drug Pipeline Sales Value (2020-2031)
- 6.8.2 Asia-Pacific NASH Drug Pipeline Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America NASH Drug Pipeline Sales Value (2020-2031)
- 6.9.2 South America NASH Drug Pipeline Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa NASH Drug Pipeline Sales Value (2020-2031)
- 6.10.2 Middle East & Africa NASH Drug Pipeline Sales Value Share by Country, 2024 VS 2031
- 7 NASH Drug Pipeline Country-level Sales and Value Analysis
- 7.1 Global NASH Drug Pipeline Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global NASH Drug Pipeline Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global NASH Drug Pipeline Sales by Country (2020-2031)
- 7.3.1 Global NASH Drug Pipeline Sales by Country (2020-2025)
- 7.3.2 Global NASH Drug Pipeline Sales by Country (2026-2031)
- 7.4 Global NASH Drug Pipeline Sales Value by Country (2020-2031)
- 7.4.1 Global NASH Drug Pipeline Sales Value by Country (2020-2025)
- 7.4.2 Global NASH Drug Pipeline Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.5.2 USA NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.9.2 France NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.16.2 China NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.19.2 India NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt NASH Drug Pipeline Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt NASH Drug Pipeline Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt NASH Drug Pipeline Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 89bio Inc
- 8.1.1 89bio Inc Comapny Information
- 8.1.2 89bio Inc Business Overview
- 8.1.3 89bio Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.1.4 89bio Inc NASH Drug Pipeline Product Portfolio
- 8.1.5 89bio Inc Recent Developments
- 8.2 ABIONYX Pharma SA
- 8.2.1 ABIONYX Pharma SA Comapny Information
- 8.2.2 ABIONYX Pharma SA Business Overview
- 8.2.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.2.4 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio
- 8.2.5 ABIONYX Pharma SA Recent Developments
- 8.3 Abivax SA
- 8.3.1 Abivax SA Comapny Information
- 8.3.2 Abivax SA Business Overview
- 8.3.3 Abivax SA NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Abivax SA NASH Drug Pipeline Product Portfolio
- 8.3.5 Abivax SA Recent Developments
- 8.4 Abliva AB
- 8.4.1 Abliva AB Comapny Information
- 8.4.2 Abliva AB Business Overview
- 8.4.3 Abliva AB NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Abliva AB NASH Drug Pipeline Product Portfolio
- 8.4.5 Abliva AB Recent Developments
- 8.5 Acquist Therapeutics
- 8.5.1 Acquist Therapeutics Comapny Information
- 8.5.2 Acquist Therapeutics Business Overview
- 8.5.3 Acquist Therapeutics NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Acquist Therapeutics NASH Drug Pipeline Product Portfolio
- 8.5.5 Acquist Therapeutics Recent Developments
- 8.6 AdAlta Ltd
- 8.6.1 AdAlta Ltd Comapny Information
- 8.6.2 AdAlta Ltd Business Overview
- 8.6.3 AdAlta Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.6.4 AdAlta Ltd NASH Drug Pipeline Product Portfolio
- 8.6.5 AdAlta Ltd Recent Developments
- 8.7 Afimmune Biopharma Ltd
- 8.7.1 Afimmune Biopharma Ltd Comapny Information
- 8.7.2 Afimmune Biopharma Ltd Business Overview
- 8.7.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio
- 8.7.5 Afimmune Biopharma Ltd Recent Developments
- 8.8 Allergan
- 8.8.1 Allergan Comapny Information
- 8.8.2 Allergan Business Overview
- 8.8.3 Allergan NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Allergan NASH Drug Pipeline Product Portfolio
- 8.8.5 Allergan Recent Developments
- 8.9 ChemomAb Ltd
- 8.9.1 ChemomAb Ltd Comapny Information
- 8.9.2 ChemomAb Ltd Business Overview
- 8.9.3 ChemomAb Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.9.4 ChemomAb Ltd NASH Drug Pipeline Product Portfolio
- 8.9.5 ChemomAb Ltd Recent Developments
- 8.10 Dicerna Pharmaceuticals Inc
- 8.10.1 Dicerna Pharmaceuticals Inc Comapny Information
- 8.10.2 Dicerna Pharmaceuticals Inc Business Overview
- 8.10.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
- 8.10.5 Dicerna Pharmaceuticals Inc Recent Developments
- 8.11 DURECT Corp
- 8.11.1 DURECT Corp Comapny Information
- 8.11.2 DURECT Corp Business Overview
- 8.11.3 DURECT Corp NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.11.4 DURECT Corp NASH Drug Pipeline Product Portfolio
- 8.11.5 DURECT Corp Recent Developments
- 8.12 Eli Lilly and Co
- 8.12.1 Eli Lilly and Co Comapny Information
- 8.12.2 Eli Lilly and Co Business Overview
- 8.12.3 Eli Lilly and Co NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Eli Lilly and Co NASH Drug Pipeline Product Portfolio
- 8.12.5 Eli Lilly and Co Recent Developments
- 8.13 Enanta Pharmaceuticals Inc
- 8.13.1 Enanta Pharmaceuticals Inc Comapny Information
- 8.13.2 Enanta Pharmaceuticals Inc Business Overview
- 8.13.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
- 8.13.5 Enanta Pharmaceuticals Inc Recent Developments
- 8.14 EncuraGen Inc
- 8.14.1 EncuraGen Inc Comapny Information
- 8.14.2 EncuraGen Inc Business Overview
- 8.14.3 EncuraGen Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.14.4 EncuraGen Inc NASH Drug Pipeline Product Portfolio
- 8.14.5 EncuraGen Inc Recent Developments
- 8.15 Engitix Ltd
- 8.15.1 Engitix Ltd Comapny Information
- 8.15.2 Engitix Ltd Business Overview
- 8.15.3 Engitix Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Engitix Ltd NASH Drug Pipeline Product Portfolio
- 8.15.5 Engitix Ltd Recent Developments
- 8.16 Galectin
- 8.16.1 Galectin Comapny Information
- 8.16.2 Galectin Business Overview
- 8.16.3 Galectin NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Galectin NASH Drug Pipeline Product Portfolio
- 8.16.5 Galectin Recent Developments
- 8.17 Genfit
- 8.17.1 Genfit Comapny Information
- 8.17.2 Genfit Business Overview
- 8.17.3 Genfit NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Genfit NASH Drug Pipeline Product Portfolio
- 8.17.5 Genfit Recent Developments
- 8.18 Gilead
- 8.18.1 Gilead Comapny Information
- 8.18.2 Gilead Business Overview
- 8.18.3 Gilead NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Gilead NASH Drug Pipeline Product Portfolio
- 8.18.5 Gilead Recent Developments
- 8.19 Heprotech Inc
- 8.19.1 Heprotech Inc Comapny Information
- 8.19.2 Heprotech Inc Business Overview
- 8.19.3 Heprotech Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Heprotech Inc NASH Drug Pipeline Product Portfolio
- 8.19.5 Heprotech Inc Recent Developments
- 8.20 Hinova Pharmaceuticals Inc
- 8.20.1 Hinova Pharmaceuticals Inc Comapny Information
- 8.20.2 Hinova Pharmaceuticals Inc Business Overview
- 8.20.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.20.4 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
- 8.20.5 Hinova Pharmaceuticals Inc Recent Developments
- 8.21 HK inno.N Corp
- 8.21.1 HK inno.N Corp Comapny Information
- 8.21.2 HK inno.N Corp Business Overview
- 8.21.3 HK inno.N Corp NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.21.4 HK inno.N Corp NASH Drug Pipeline Product Portfolio
- 8.21.5 HK inno.N Corp Recent Developments
- 8.22 HotSpot Therapeutics Inc
- 8.22.1 HotSpot Therapeutics Inc Comapny Information
- 8.22.2 HotSpot Therapeutics Inc Business Overview
- 8.22.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.22.4 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio
- 8.22.5 HotSpot Therapeutics Inc Recent Developments
- 8.23 Immuron
- 8.23.1 Immuron Comapny Information
- 8.23.2 Immuron Business Overview
- 8.23.3 Immuron NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.23.4 Immuron NASH Drug Pipeline Product Portfolio
- 8.23.5 Immuron Recent Developments
- 8.24 Intercept
- 8.24.1 Intercept Comapny Information
- 8.24.2 Intercept Business Overview
- 8.24.3 Intercept NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.24.4 Intercept NASH Drug Pipeline Product Portfolio
- 8.24.5 Intercept Recent Developments
- 8.25 Madrigal
- 8.25.1 Madrigal Comapny Information
- 8.25.2 Madrigal Business Overview
- 8.25.3 Madrigal NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.25.4 Madrigal NASH Drug Pipeline Product Portfolio
- 8.25.5 Madrigal Recent Developments
- 8.26 Zhejiang Doer Biologics Corp
- 8.26.1 Zhejiang Doer Biologics Corp Comapny Information
- 8.26.2 Zhejiang Doer Biologics Corp Business Overview
- 8.26.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Value and Gross Margin (2020-2025)
- 8.26.4 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio
- 8.26.5 Zhejiang Doer Biologics Corp Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 NASH Drug Pipeline Value Chain Analysis
- 9.1.1 NASH Drug Pipeline Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 NASH Drug Pipeline Sales Mode & Process
- 9.2 NASH Drug Pipeline Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 NASH Drug Pipeline Distributors
- 9.2.3 NASH Drug Pipeline Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.